Skip to main content

Table 2 Distribution of SNPs in IL-27 among patients and controls and their association with bladder cancer risk

From: Polymorphisms and plasma levels of IL-27: impact on genetic susceptibility and clinical outcome of bladder cancer

  

rs153109

rs17855750

Model

Genotype

Controls

patients

OR (95 % CI)a

P valuea

Genotype

Controls

patients

OR (95 % CI)a

P valuea

N = 499 (%)

N = 332 (%)

N = 499 (%)

N = 332 (%)

Codominant

AA

229 (45.9)

127 (38.2 %)

1.00 (reference)

0.075

TT

421 (84.4)

275 (82.8 %)

1.00 (reference)

0.022

AG

204 (40.9)

160 (48.2 %)

1.41 (1.05–1.92)

TG

78 (15.6)

53 (16.0 %)

0.97 (0.66–1.42)

GG

66 (13.2)

45 (13.6 %)

1.23 (0.79–1.89)

GG

0

4 (1.2 %)

0.00 (0.00-NA)

Dominant

AA

229 (45.9)

127 (38.2 %)

1.00 (reference)

0.029

TT

421 (84.4)

275 (82.8 %)

1.00 (reference)

0.57

AG/GG

270 (54.1)

205 (61.8 %)

1.37 (1.03–1.82)

TG/GG

78 (15.6)

57 (17.2 %)

0.90 (0.62–1.31)

Recessive

AA/AG

433 (86.8)

287 (86.5 %)

1.00 (reference)

0.9

TT/TG

499 (100)

328 (98.8 %)

1.00 (reference)

0.006

GG

66 (13.2)

45 (13.6 %)

1.03 (0.68–1.54)

GG

0 (0)

4 (1.2 %)

0.00 (0.00-NA)

Overdominant

AA/GG

295 (59.1)

172 (51.8 %)

1.00 (reference)

0.037

TT/GG

421 (84.4)

279 (84.0 %)

1.00 (reference)

0.92

AG

204 (40.9)

160 (48.2 %)

1.35 (1.02–1.79)

TG

78 (15.6)

53 (16.0 %)

0.98 (0.59–1.19)

 

Allele

         
 

A

662 (66.3)

414 (62.3)

1.19 (0.97–1.46)

0.096

T

920 (92.2)

603 (90.8)

1.20 (0.84–1.70)

0.317

 

G

336 (33.7)

250 (37.7)

G

78 (7.8)

61 (9.2)

  1. N corresponds to the number of individuals
  2. aAdjusted by age, sex and smoking status
  3. Boldfaced values indicate a significant difference at the 5 % level
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us